Aram Modrek

Aram Modrek is an Assistant Professor of Radiation Oncology and Cancer Biology in the Department of Radiation Oncology at the Keck School of Medicine of the University of Southern California. He serves as Culture and Engagement Champion for the Department and is an active member of the USC Norris Comprehensive Cancer Center, Epigenetic Regulation in Cancer Program, and USC Brain Tumor Center.

Dr. Modrek's research centers on DNA damage-induced genomic alterations and their impact on gene regulation in brain tumors, with particular focus on treatment resistance mechanisms. His lab employs cutting-edge genomic and transcriptomic approaches to investigate how cancer cells adapt to therapy, aiming to develop strategies that disrupt these adaptive processes. Key research areas include radiation biology, glioblastoma pathogenesis, epigenetic regulation, and molecular mechanisms of therapeutic resistance.

His publication record demonstrates consistent productivity with 15+ recent articles spanning radiation oncology, cancer biology, and neuro-oncology. Research themes prominently feature brain tumor genomics, DNA damage response pathways, and translational applications of molecular findings. Recent work includes investigations into platelet transcriptomes in cancer, radiation resistance mechanisms in glioblastoma, and novel therapeutic targets like PDPN and GPR133.

No scientific awards were explicitly mentioned in the source material.

Dr. Modrek leads the Modrek Lab with support from external funding sources, though specific grants aren't detailed in the provided text. His work bridges basic science and clinical applications, evidenced by publications spanning molecular mechanisms to clinical decision support tools. The lab operates within USC's robust cancer research infrastructure, collaborating across multiple centers including the Brain Tumor Center.

The Modrek Lab functions within the Department of Radiation Oncology at USC, actively participating in the university's cancer research ecosystem through the Norris Comprehensive Cancer Center and specialized programs focused on brain tumors and epigenetic regulation.